Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vir Biotechnology, Inc. - Common Stock
(NQ:
VIR
)
5.170
-0.140 (-2.64%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 27, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vir Biotechnology, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...
Via
Benzinga
Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
February 28, 2022
Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
February 23, 2022
On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...
Via
Benzinga
AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants
February 25, 2022
The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ: AZN) pre-exposure prophylaxis drug Evusheld (tixagevimab and cilgavimab)....
Via
Benzinga
Recap: Vir Biotechnology Q4 Earnings
February 24, 2022
Vir Biotechnology (NASDAQ:VIR) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
World Markets News For Thursday
February 17, 2022
Ericsson stock lost another 5.27% today in US markets.
Via
Talk Markets
Give peace a chance
February 15, 2022
Israeli fabless semiconductor maker Tower was bought by Intel for $5.4 bn today.
Via
Talk Markets
Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant
February 10, 2022
In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc (NYSE
Via
Benzinga
Inflation inflating
February 10, 2022
The Fed will be raising interest rates soon and this will chop the appeal of investments in more vulnerable yield plays.
Via
Talk Markets
Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus
February 08, 2022
Immunome Inc (NASDAQ: IMNM) shares rose before falling after reporting results from testing its experimental three-antibody cocktail
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
February 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Panic reversal
January 26, 2022
Crude oil inventories turned out to be fuller than expected, helping reduce the oil price rise.
Via
Talk Markets
WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge
January 14, 2022
An expert panel at the World Health Organization (WHO) recommended the use of treatments developed by Eli Lilly And Co (NYSE: LLY) and GlaxoSmithKline Plc...
Via
Benzinga
GSK, Vir Biotech File For Emergency Use Nod For Intramuscular Sotrovimab For COVID-19
January 13, 2022
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have applied to the FDA to include intramuscular (IM) administration to sotrovimab...
Via
Benzinga
Vir Biotechnology Expands Partnership With Bill & Melinda Gates Foundation, Launches New Antibody Research Initiative Aimed At A Functional Cure For HIV And Prevention Of Malaria; Foundation Has Committed $40M Equity Investment And $10M Grant
January 13, 2022
Vir Biotechnology, Inc. (NASDAQ: VIR) today announced an expansion of its partnership with the Bill & Melinda Gates Foundation to include the advancement of innovative...
Via
Benzinga
Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies
January 13, 2022
Adagio Therapeutics Inc (NASDAQ: ADGI) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron...
Via
Benzinga
20 Stocks Moving in Thursday's Pre-Market Session
January 13, 2022
Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday. Adagio Therapeutics, Inc. (NASDAQ: ADGI) rose 22.8% to $7.16 in pre-...
Via
Benzinga
US To Purchase 600K Additional Doses of GSK-Vir's COVID-19 Antibody Therapy
January 11, 2022
The U.S. has agreed to buy 600,000 more doses of GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) COVID-19 antibody...
Via
Benzinga
50 Biggest Movers From Yesterday
January 13, 2022
Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after the company's gammaCore nVNS device received FDA Breakthrough Designation for...
Via
Benzinga
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
December 29, 2021
Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The...
Via
Benzinga
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus
December 26, 2021
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key...
Via
Talk Markets
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
December 26, 2021
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating...
Via
Benzinga
Xmas Eve
December 24, 2021
About 2000 flights which airlines were proposing to run today have been canceled because of virus not only amongst passengers but also among the crew.
Via
Talk Markets
Plague Year Reversal
December 21, 2021
Just in time for Christmas, the market decided to go up today pretty much across the board.
Via
Talk Markets
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 21, 2021
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4...
Via
Benzinga
55 Biggest Movers From Yesterday
December 22, 2021
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8...
Via
Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
December 21, 2021
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining...
Via
Benzinga
Alibaba Downgrade, Micron Upgrades Among Today's Top Calls On Wall Street
December 21, 2021
Atlantic Equities analyst James Cordwell downgraded Alibaba to Neutral from Overweight with a price target of $140, down from $185.
Via
Talk Markets
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.